Skip to Content
Merck
  • Trends in pharmacy compounding for women's health in North Carolina: focus on vulvodynia.

Trends in pharmacy compounding for women's health in North Carolina: focus on vulvodynia.

Southern medical journal (2014-07-11)
Susan H Corbett, Gary Cuddeback, Jasmine Lewis, Swasan As-Sanie, Denniz Zolnoun
ABSTRACT

To identify trends in compounding pharmacies with a focus on women's health and, more specifically, the types and combinations of medications used in the treatment of vulvodynia. This survey study was conducted with 653 nonchain pharmacies that compound medications. Each pharmacy was asked to complete a 19-item online survey assessing general practice and common compounding indications, focusing on women's health. Of the 653 pharmacies contacted, 200 (31%) responded to our survey. Women's health issues ranked third (19%) among the common indications for compounding, preceded by otolaryngology (30%) and dermatology (28%). Of the medications compounded for women's health, the most common indication was bioidentical hormone therapy (73%) followed closely by vaginal dryness (70%) and low libido (65%). Vulvodynia, or vulvar pain, was the fourth most common indication for compounding medication for women's health issues (29%). Vulvovaginal infections were reported as an indication for compounding medications by 16% of respondents. Vulvovaginal symptoms are a common indication for compounding medications in women's health. Further research in understanding the rationale for using compounded medications, even when standard treatments are available for some of these symptoms (eg, vaginal dryness, vulvovaginal infections), is warranted.

MATERIALS
Product Number
Brand
Product Description

Supelco
Lidocaine, Pharmaceutical Secondary Standard; Certified Reference Material
Testosterone, European Pharmacopoeia (EP) Reference Standard
Progesterone, European Pharmacopoeia (EP) Reference Standard
Supelco
Progesterone, Pharmaceutical Secondary Standard; Certified Reference Material
Lidocaine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Lidocaine, European Pharmacopoeia (EP) Reference Standard
Supelco
Progesterone, VETRANAL®, analytical standard
Supelco
Testosterone, VETRANAL®, analytical standard
Sigma-Aldrich
Progesterone, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Progesterone, γ-irradiated, BioXtra, suitable for cell culture
Sigma-Aldrich
Lidocaine, powder
Sigma-Aldrich
β-Estradiol, powder, γ-irradiated, suitable for cell culture
Sigma-Aldrich
β-Estradiol, BioReagent, powder, suitable for cell culture
Sigma-Aldrich
Testosterone, ≥98%
Sigma-Aldrich
Lidocaine, analytical standard
Sigma-Aldrich
Lidocaine hydrochloride monohydrate, solid
Supelco
Testosterone solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Lidocaine hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Lidocaine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
USP
Lidocaine, United States Pharmacopeia (USP) Reference Standard
USP
Progesterone, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Progesterone, meets USP testing specifications
Sigma-Aldrich
Progesterone, ≥99%
Sigma-Aldrich
Estriol, meets USP testing specifications
Sigma-Aldrich
β-Estradiol, ≥98%
Sigma-Aldrich
β-Estradiol, analytical standard
Estradiol hemihydrate, European Pharmacopoeia (EP) Reference Standard
Supelco
Progesterone solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
17β-Estradiol solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Estriol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®